<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02388048</url>
  </required_header>
  <id_info>
    <org_study_id>LLC1215</org_study_id>
    <secondary_id>2015-000684-13</secondary_id>
    <nct_id>NCT02388048</nct_id>
  </id_info>
  <brief_title>Ofatumumab &amp; Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia</brief_title>
  <official_title>A Phase II Study of the Combination of Ofatumumab and Ibrutinib Followed by Allogeneic Bone Marrow Transplant or Consolidation for Pretreated High Risk Patients With Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical study to evaluate a treatment with two drugs, named Ofatumumab and Ibrutinib, in
      patients with lymphoblastic acute leukemia who have been already treated with other
      therapies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II multicenter, non-comparative, open label study for high risk previously
      treated patients with CLL, requiring therapy, aimed at evaluating the efficacy of the
      Ofatumumab and Ibrutinib combination.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of pretreated patients with high risk CLL who achieve a Complete Response (CR) after the induction therapy with Ibrutinib plus Ofatumumab.</measure>
    <time_frame>After 6.5 years from treatment start</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients in Complete Response (CR)/Partial Response (PR)</measure>
    <time_frame>After 28 weeks from treatment start</time_frame>
    <description>Overall response rate at the end of induction therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients without progression of the disease.</measure>
    <time_frame>At 60 months from treatment start</time_frame>
    <description>Progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients alive</measure>
    <time_frame>At 60 months from treatment start</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients without events</measure>
    <time_frame>At 60 months from treatment start</time_frame>
    <description>Event-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Minimal Residual Disease-negative Complete Responses</measure>
    <time_frame>At 28 weeks from treatment start</time_frame>
    <description>6. To estimate Minimal Residual Disease (MRD) in terms of rate of MRD-negative CRs at the end of induction therapy and after SCT or Ibrutinib maintenance therapy for patients in CR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>At 6.5 years after treatment start</time_frame>
    <description>7. Safety profile and tolerability of the combination of Ofatumumab and Ibrutinib and the ibrutinib as maintenance in terms of type, frequency, severity and relationship of adverse events (AEs).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">79</enrollment>
  <condition>Leukemia, Lymphoblastic, Chronic</condition>
  <arm_group>
    <arm_group_label>Ibrutinib + Ofatumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IBRUTINIB 420 mg PO daily in 28-day cycles for a total of 7 cycles (28 weeks).
OFATUMUMAB 300 mg on day 1 of cycle 2 of Ibrutinib, followed by 2000 mg on D8, 15, 22 of cycle 2, D1, 8, 15, 22 of cycle 3, and Day 1 of cycle 4-7.
After induction treatment patients with HLA identical sibling or fully matched MUD donor will be addressed to reduced intensity allogeneic bone marrow transplant, while patients without a suitable donor or who refuse the transplant procedure will receive maintenance treatment by BTK inhibitor (IBRUTINIB 420 mg PO daily in 28-day cycles). Treatment will continue until disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib + ofatumumab</intervention_name>
    <arm_group_label>Ibrutinib + Ofatumumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, age 18 years or until 65 years;

          2. Confirmation of B-CLL previously treated with no more than 1 previous line of
             treatment .

          3. Risk patients with CLL defined as follows:

               -  treated patients showing 17p deletion in &gt;20% of the cells by FISH, or TP53
                  mutation or,

               -  resistant (SD/PD) to fludarabine containing combination therapy or relapse within
                  12 months from a fludarabine-containing combination therapy.

          4. Active disease meeting at least 1 of the following IWCLL criteria for requiring
             treatment:

               -  Evidence of progressive marrow failure as manifested by the development of, or
                  worsening of anemia (Hb&lt; 10 g/dL) and/or thrombocytopenia (platelets &lt;
                  100,000/mL).

               -  Massive (≥ 6 cm below the left costal margin), progressive, or symptomatic
                  splenomegaly.

               -  Massive nodes (at least 10 cm longest diameter), or progressive or symptomatic
                  lymphadenopathy.

               -  Progressive lymphocytosis with an increase of more than 50% over a 2-month period
                  or a lymphocyte doubling time (LDT) of &lt; 6 months.

               -  Autoimmune hemolytic anemia and/or immune thrombocytopenia that is poorly
                  responsive to corticosteroids or other standard therapy.

               -  One or more disease-related symptoms:

               -  unintentional weight loss &gt; 10% within 6 months prior to screening;

               -  significant fatigue (inability to work or perform usual activities);

               -  fevers &gt;38.0°C for 2 or more weeks prior to screening;

               -  night sweats for more than 1 month prior to screening.

          5. Stage B or C of CLL according to Binet staging system;

          6. Stage A disease fitting the criteria for treatment according to the IWCLL-NCI criteria
             (2008) are also included.

          7. WHO performance status 0-II.

          8. Life expectancy ≥ 6 months.

          9. Hematology values must be within the following limits:

               -  Absolute neutrophil count (ANC) ≥ 750/mm3 independent of growth factor support;

               -  Platelets ≥100,000/mm3 or ≥ 30.000/mm3 if bone marrow involvement independent of
                  transfusion support in either situation.

         10. Biochemical values within the following limits:

               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x upper
                  limit of normal (ULN).

               -  Total bilirubin ≤ 1.5 x ULN unless bilirubin rise is due to Gilbert's syndrome or
                  of non-hepatic origin.

               -  Serum creatinine ≤ 2 x ULN or estimated Glomerular Filtration Rate (Cockroft
                  Gault) ≥ 30 mL/min/1.73m2.

         11. Women of childbearing potential and men who are sexually active must be practicing a
             highly effective method of birth control during and after the study For females, these
             restrictions apply for 1 month after the last dose of ibrutinib and for 12 months
             after the last dose of Ofatumumab. For males, these restrictions apply for 3 months
             after the last dose of ibrutinib. Men must agree to not donate sperm during and after
             the study.

         12. Women of childbearing potential must have a negative serum (beta-human chorionic
             gonadotropin [β-hCG]) or urine pregnancy test at Screening. Women who are pregnant or
             breastfeeding are ineligible for this study.

         13. Sign an informed consent document indicating that they understand the purpose of and
             procedures required for the study, including biomarkers, and are willing to
             participate in the study.

        Exclusion Criteria:

          1. Major surgery within 3 weeks before registration.

          2. Known central nervous system lymphoma.

          3. History of stroke or intracranial hemorrhage within 6 months prior to registration.

          4. Requires anticoagulation with warfarin or equivalent vitamin K antagonists (eg,
             phenprocoumon).

          5. Clinically significant cardiovascular disease such as uncontrolled or symptomatic
             arrhythmias, congestive heart failure, or myocardial infarction within 6 months of
             Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by
             the New York Heart Association Functional Classification.

          6. Vaccinated with live, attenuated vaccines within 4 weeks of registration.

          7. Known history of human immunodeficiency virus (HIV) or active Hepatitis C Virus or
             active Hepatitis B Virus infection or any uncontrolled active systemic infection
             requiring intravenous (IV) antibiotics.

          8. Any life-threatening illness, medical condition, or organ system dysfunction which, in
             the investigator's opinion, could compromise the subject's safety, interfere with the
             absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue
             risk.

          9. Positive serology for Hepatitis B (HB) defined as a positive test for HBsAg. In
             addition, if negative for HBsAg but HBcAb positive (regardless of HBsAb status), a
             HBDNA test will be performed and if positive the subject will be excluded. ***see
             attached monitoring criteria for HBcAb+ and HBV DNA negative subjects.

         10. Other past or current malignancy. Subjects who have been free of malignancy for at
             least 5 years, or have a history of completely resected non-melanoma skin cancer, or
             successfully treated in situ carcinoma are eligible.

         11. Requirement for treatment with a strong CYP3A4/5 and/or CYP2D6 inhibitor.

         12. Significant concurrent, uncontrolled medical condition including, but not limited to,
             renal, hepatic, gastrointestinal, endocrine, pulmonary, neurological, cerebral or
             psychiatric disease which in the opinion of the investigator may represent a risk for
             the patient.

         13. Inability to swallow capsules or tablets, or disease significantly affecting
             gastrointestinal function and/or inhibiting small intestine absorption.

         14. Chronic or current infectious disease requiring systemic antibiotics, antifungal, or
             antiviral treatment such as, but not limited to, chronic renal infection, chronic
             chest infection with bronchiectasis, tuberculosis.

         15. Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura.

         16. Central nervous system involvement with CLL.

         17. Subjects who have current active hepatic or biliary disease (with exception of
             patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable
             chronic liver disease per investigator assessment).

         18. Treatment with any known non-marketed drug substance or experimental therapy within 5
             terminal half lives or 4 weeks prior to enrollment, whichever is longer, or currently
             participating in any other interventional clinical study.

         19. Prior treatment with anti-CD20 monoclonal antibody or alemtuzumab within 3 months
             prior to the start of therapy.

         20. History of significant cerebrovascular disease in the past 6 months or ongoing event
             with active symptoms or sequelae.

               -  If HBV DNA is negative, subject may be included but must undergo at least every 2
                  month HBV DNA PCR testing from the start of treatment during the treatment
                  course. Prophylactic antiviral therapy may be initiated at the discretion of the
                  investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Montillo</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Hematology, Niguarda Ca' Granda, Milan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesca R. Mauro</last_name>
    <role>Study Director</role>
    <affiliation>Department of Hematology, Policlinico Umberto I di Roma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paola Fazi</last_name>
    <email>p.fazi@gimema.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enrico Crea</last_name>
    <email>e.crea@gimema.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Università degli Studi &quot;Sapienza&quot; - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia</name>
      <address>
        <city>Roma</city>
        <state>Provincia</state>
        <zip>00141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca R. Mauro</last_name>
    </contact>
    <investigator>
      <last_name>Francesca R. Mauro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Pietrasanta</last_name>
    </contact>
    <investigator>
      <last_name>Daniela Pietrasanta</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisa Bernocco</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nuovo Record Esporta in Excel Stampa Esporta in file di testo Mostra Informazioni Record Multi edit Stato dello studio presso il centro records: 28 Record 1/28 su 28 direzione di ordinamento Centro (CIC) direzione di ordinamento Sperimentatore Pri</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierluigi Zinzani</last_name>
    </contact>
    <investigator>
      <last_name>Pierluigi Zinzani</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vittorio Stefoni</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASL N.8 - Ospedale &quot;A. Businco&quot; - Struttura Complessa di Ematologia e CTMO</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberta Murru</last_name>
    </contact>
    <investigator>
      <last_name>Roberta Murru</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefania Massidda</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università di Catania - Cattedra di Ematologia - Ospedale &quot;Ferrarotto&quot;</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Di Raimondo</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Di Raimondo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Pugliese Ciaccio - Presidio Ospedaliero A.Pugliese - Unità Operativa di Ematologia</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Molica</last_name>
    </contact>
    <investigator>
      <last_name>Stefano Molica</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rosanna Mirabelli</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nuovo Record Esporta in Excel Stampa Esporta in file di testo Mostra Informazioni Record Multi edit Stato dello studio presso il centro records: 28 Record 1/28 su 28 direzione di ordinamento Centro (CIC) direzione di ordinamento Sperimentatore Pri</name>
      <address>
        <city>Cona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Cuneo</last_name>
    </contact>
    <investigator>
      <last_name>Antonio Cuneo</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gian Matteo Rigolin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia - P.O. Annunziata - A.O. di Cosenza</name>
      <address>
        <city>Cosenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fortunato Morabito</last_name>
    </contact>
    <investigator>
      <last_name>Fortunato Morabito</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Massimo Gentile</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico di Careggi</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alberto Bosi</last_name>
    </contact>
    <investigator>
      <last_name>Alberto Bosi</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefania Ciolli</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS_AOU San Martino-IST-Ematologia 1-Monoblocco 11°piano- lato ponente</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angelo Michele Carella</last_name>
    </contact>
    <investigator>
      <last_name>Angelo Michele Carella</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Di Renzo</last_name>
    </contact>
    <investigator>
      <last_name>Nicola Di Renzo</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Raffaela Fadda</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnoli per lo Studio e la Cura dei Tumori- IRST</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Ronconi</last_name>
    </contact>
    <investigator>
      <last_name>Sonia Ronconi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia - Azienda Ospedaliera Ospedali Riuniti &quot;Papardo Piemonte&quot; P.O. Papardo</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donato Mannina</last_name>
    </contact>
    <investigator>
      <last_name>Donato Mannina</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Nocilli</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Niguarda &quot; Ca Granda&quot; - SC Ematologia Blocco SUD, Ponti Est, Scala E, 4° piano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Montillo</last_name>
    </contact>
    <investigator>
      <last_name>Marco Montillo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ginlunca Gaidano</last_name>
    </contact>
    <investigator>
      <last_name>Gianluca Gaidano</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lorenzo De Paoli</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. di Ematologia con trapianto - Centro di Riferimento Regionale per le coagulopatie rare nel bambino e nell'adulto Dipart. Biomedico di Medicina Interna - A.U. Policlinico &quot;Paolo Giaccone&quot;</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sergio Siragusa</last_name>
    </contact>
    <investigator>
      <last_name>Sergio Siragusa</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Grazia Lipari</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cattedra di Ematologia CTMO Università degli Studi di Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesca Re</last_name>
    </contact>
    <investigator>
      <last_name>Francesca Re</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Filomena Russo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sezione di Ematologia ed Immunologia Clinica - Ospedale S.Maria della Misericordia</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brunangelo Falini</last_name>
    </contact>
    <investigator>
      <last_name>Brunangelo Falini</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Franca Falzetti</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia Clinica - Azienda USL di Pescara</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Angrilli</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Angrilli</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erica Finolezzi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Complessa di Ematologia - Arcispedale S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiorella Ilariucci</last_name>
    </contact>
    <investigator>
      <last_name>Fiorella Ilariucci</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabel Alvarez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Infermi&quot;</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Lia Molinari</last_name>
    </contact>
    <investigator>
      <last_name>Anna Lia Molinari</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrizia Tosi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università Cattolica del Sacro Cuore - Policlinico A. Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luca Laurenti</last_name>
    </contact>
    <investigator>
      <last_name>Luca Laurenti</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Idanna Innocenti</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università degli Studi - Policlinico di Tor Vergata</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sergio Amadori</last_name>
    </contact>
    <investigator>
      <last_name>Sergio Amadori</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Ilaira Del Principe</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Santa Maria - Terni S.C Oncoematologia</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Marina Liberati</last_name>
    </contact>
    <investigator>
      <last_name>Anna Marina Liberati</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ilaria Angeletti</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Mauriziano Umberto I</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimo Massaia</last_name>
    </contact>
    <investigator>
      <last_name>Massimo Massaia</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniela Gottardi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Oncologia ed Ematologia S.C. Ematologia 2 A.O. Città della Salute e della Scienza di Torino San Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lorella Orsucci</last_name>
    </contact>
    <investigator>
      <last_name>Lorella Orsucci</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carola Boccomini</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia dell' Università degli Studi di Torino - &quot;Città della Salute e della Scienza di Torino&quot;</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marta Coscia</last_name>
    </contact>
    <investigator>
      <last_name>Marta Coscia</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benedetto Bruno</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Verona - A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dino Veneri</last_name>
    </contact>
    <investigator>
      <last_name>Dino Veneri</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emanuele Guardalben</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2015</study_first_submitted>
  <study_first_submitted_qc>March 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2015</study_first_posted>
  <last_update_submitted>August 31, 2017</last_update_submitted>
  <last_update_submitted_qc>August 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Chronic</keyword>
  <keyword>High-risk</keyword>
  <keyword>ofatumumab</keyword>
  <keyword>ibrutinib</keyword>
  <keyword>Lymphoblastic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ofatumumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

